World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases

Berman Tabacco, Sperling Kenny Nachwalter, LLC and Hilliard Shadowen LLP Announce a Class Action Settlement If You Purchased, Paid For, or Provided Reimbursement for QVAR® and/or QVAR RediHaler® Inhalers From January 1, 2015 through July 31, 2025

Cision PR Newswire by Cision PR Newswire
May 1, 2026
in Press Releases
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

SAN FRANCISCO, May 1, 2026 /PRNewswire/ —

Legal Notice

Did You Purchase, Pay for, or Provide Reimbursement for QVAR® and/or QVAR RediHaler® Inhalers?
You Could Get Money from a Settlement.

There is a Settlement in a class action lawsuit with Teva Pharmaceutical Industries Ltd.; Teva Pharmaceuticals USA, Inc.; Teva Branded Pharmaceutical Products R&D, Inc.; and Norton (Waterford) Ltd. (collectively, “Teva”). The lawsuit claims that Teva unlawfully kept generic versions of QVAR® and QVAR RediHaler® off the market, so consumers and third-party payors paid more for QVAR® and QVAR RediHaler® inhalers than they should have. Teva denies it did anything wrong. No one is claiming that QVAR® or QVAR RediHaler® Products are unsafe.

Who is included in the Settlement?

You may be included in the Settlement if you are a person or entity that, for consumption by yourself, your families, or your members, insureds, or beneficiaries, purchased, paid, and/or provided reimbursement for some or all of the purchase price of QVAR® and/or QVAR RediHaler® inhalers, from January 1, 2015, through July 31, 2025, other than for resale, in the following states and territories: Alaska, Arkansas, Arizona, California, Connecticut, Delaware, D.C., Florida, Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Massachusetts, Maryland, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.

A more detailed notice, including the full class definition and who is not included, is available at www.QVARAntitrustSettlement.com. 

What does the Settlement provide?

Teva will pay $35 million into a Settlement Fund that will pay (1) money to eligible Class Members; (2) notice and administration costs; (3) service awards to the class representatives who brought the lawsuit; and (4) attorneys’ fees, costs, and expenses. Teva will also remove/delist certain patents from the Food and Drug Administration’s Orange Book, removing certain barriers to bringing generic versions of QVAR® to market.

How can I get a payment?

You must submit a valid Claim Form to apply for payment from the Settlement Fund. The amount of your payment will depend on the amount of QVAR® and QVAR RediHaler® products you purchased, the number of valid claims filed, and the amount of purchases represented by those valid claims. Claim Forms, and information on how to submit them, are available at www.QVARAntitrustSettlement.com. Claim Forms must be postmarked (if mailed) or received (if submitted online) on or before July 31, 2026.

What are my rights?

Even if you do nothing, you will be bound by the Court’s decisions. If you want to keep your right to sue Teva yourself, you must exclude yourself by June 15, 2026. If you do not exclude yourself, you may object to the Settlement by June 15, 2026. Detailed instructions about how to act on these rights are available at www.QVARAntitrustSettlement.com. 

The Court will hold a hearing on August 5, 2026 to consider whether to approve the Settlement, a request for attorneys’ fees of up to 33% of the Settlement Fund, reimbursement of litigation costs and expenses up to $890,000, payment of reasonable notice and claims administration costs, and service awards of $25,000 to each of the four class representatives. You or your own lawyer may appear and speak at the hearing at your own expense. The Court may change these deadlines or the hearing date and time. Check the website below for updates. Please do not call the Court or the Clerk of the Court for information about the Settlement.

For more information: 1-866-588-8524      www.QVARAntitrustSettlement.com

Cision View original content:https://www.prnewswire.com/news-releases/berman-tabacco-sperling-kenny-nachwalter-llc-and-hilliard-shadowen-llp-announce-a-class-action-settlement-if-you-purchased-paid-for-or-provided-reimbursement-for-qvar-andor-qvar-redihaler-inhalers-from-january-1-2015-throu-302760285.html

SOURCE Berman Tabacco, Sperling Kenny Nachwalter, LLC and Hilliard Shadowen LLP

Cision PR Newswire

Cision PR Newswire

Related Posts

PhilWeb Q2 Net Income Surges 237% Q-Q on Digital Gaming Solutions Growth and AI Pilot

August 11, 2026

KuCoin Strengthens Its RWA Ecosystem with Ondo Tokenized Stocks on KuCoin Alpha

August 11, 2026

DeTect Awarded Contract to Supply MERLIN™ True3D® Bird Detection Radar to the Soekarno-Hatta Airport in Jakarta

August 11, 2026

Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

August 11, 2026

A Chinese Tower Becomes a Laboratory for the Future of Heritage

August 11, 2026

Reap Goes Live on Hyperliquid with USDC funding capabilities

August 11, 2026

Popular News

  • PhilWeb Q2 Net Income Surges 237% Q-Q on Digital Gaming Solutions Growth and AI Pilot

    0 shares
    Share 0 Tweet 0
  • KuCoin Strengthens Its RWA Ecosystem with Ondo Tokenized Stocks on KuCoin Alpha

    0 shares
    Share 0 Tweet 0
  • Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

    0 shares
    Share 0 Tweet 0
  • DeTect Awarded Contract to Supply MERLIN™ True3D® Bird Detection Radar to the Soekarno-Hatta Airport in Jakarta

    0 shares
    Share 0 Tweet 0
  • A Chinese Tower Becomes a Laboratory for the Future of Heritage

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler